BioSpace News Archive

KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarify the Company’s corporate focus, direction, and progress.

The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state.

Oppenheimer & Co. Inc. (“Oppenheimer”), a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced the successful conclusion of its 31st Annual Healthcare Conference, held virtually from March 16 through 18

March is National Colorectal Cancer Awareness Month and this year the Colon Cancer Foundation (CCF) is helping promote the importance of early detection in successfully beating the disease. CCF is honoring awareness month with a range of activities including a Virtual Concert for a Cause on Sunday,

Beckman Coulter, a clinical diagnostics leader, today announced their commitment to support the U.S. government’s plan to invest more than $12 billion to expand COVID-19 testing with their high-throughput, high-quality lab antigen test, Access SARS-CoV-2 Ag,* ideal for mass screening testing

Fujifilm to invest $2 Billion and create 725 jobs with its new state-of-the-art large-scale cell culture manufacturing facility in Holly Springs, North Carolina

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2020 as well as certain other business highlights.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, today announced its partnership with Family Reach, a national organization dedicated to eradicating the financial challenges that accompany a cancer diagnosis

Even, the solution for medication-induced nutrient depletions (MIND), today announces its brand launch and $1.5 million seed funding led by Align Ventures, Spring Street Group and GAN Ventures

-Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, will address the impact of a patient-centric approach on advancing gene therapy